Department of Ophthalmology, Glostrup Hospital, Copenhagen, Denmark Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Br J Ophthalmol. 2014 Sep;98(9):1208-11. doi: 10.1136/bjophthalmol-2013-304580. Epub 2014 Apr 12.
To investigate the effect of intravitreal injections of the vascular endothelial growth factor inhibitor ranibizumab on retinal oxygenation in patients with central retinal vein occlusion (CRVO).
Retinal oxygen saturation in patients with CRVO was analysed using the Oxymap Retinal Oximeter P3, before and during 6 months of treatment with intravitreal injections of ranibizumab.
At presentation, retinal venous oxygen saturation was lower in eyes with CRVO than in the healthy fellow eyes (32±13% vs 59±10%, respectively, p=0.001) whereas retinal arterial saturation was higher in eyes with CRVO than in the fellow eyes (95%±8% and 91%±3%, p=0.04). Mean visual acuity increased from 51±24 letters ETDRS at baseline to 66±24 and 69±20 letters ETRDS, respectively, at 3 months and 6 months treatment (mean±SD, p<0.0001, repeated measures analysis of variance) and central retinal thickness was reduced from 697±139 µm to 368±113 µm and 340±96 µm, respectively, from baseline to 3 months and 6 months treatment (p<0.0001). Venous saturation increased during treatment (from 35.5%±13.8% at baseline to 43.1%±10.8% and 43.5%±13.7% after 3 months and 6 months treatment, respectively, p=0.012), while no significant change was found in arterial saturation (p=0.24).
Retinal venous oxygen saturation was markedly reduced in untreated CRVO and was roughly halfway normalised during intravitreal ranibizumab treatment. Retinal artery oxygen saturation was not reduced in CRVO.
NCT01360385.
研究玻璃体内注射血管内皮生长因子抑制剂雷珠单抗对视网膜中央静脉阻塞（CRVO）患者视网膜氧合的影响。
使用 Oxymap 视网膜血氧计 P3 分析 CRVO 患者的视网膜氧饱和度，在接受玻璃体内雷珠单抗注射治疗的 6 个月前和期间进行分析。
在初次就诊时，CRVO 眼的视网膜静脉血氧饱和度低于健康对侧眼（分别为 32±13%和 59±10%，p=0.001），而 CRVO 眼的视网膜动脉血氧饱和度高于对侧眼（分别为 95%±8%和 91%±3%，p=0.04）。平均视力从基线时的 51±24 ETDRS 字母提高到治疗 3 个月和 6 个月时的 66±24 和 69±20 ETRDS 字母（平均值±标准差，p<0.0001，重复测量方差分析），中心视网膜厚度从 697±139µm 减少到治疗 3 个月和 6 个月时的 368±113µm 和 340±96µm（p<0.0001）。治疗期间静脉饱和度增加（从基线时的 35.5%±13.8%增加到治疗 3 个月和 6 个月时的 43.1%±10.8%和 43.5%±13.7%，p=0.012），而动脉饱和度没有明显变化（p=0.24）。
未经治疗的 CRVO 患者的视网膜静脉血氧饱和度明显降低，在玻璃体内注射雷珠单抗治疗期间大约恢复正常的一半。CRVO 中视网膜动脉氧饱和度没有降低。
NCT01360385。
